Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Health-related QoL in ipilimumab treated advanced melanoma survivors

Christian Blank • 27 Sep 2019
ESMO 2019
Melanoma Skin Cancer Checkpoint Inhibitors Ipilimumab

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Christian Blank

1:55
Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank • 16 Apr 2021
1:44
The future of adjuvant therapy in melanoma
Christian Blank • 19 Apr 2021
1:16
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank • 19 Apr 2021
1:09
Predicting resistance to targeted therapies in melanoma
Christian Blank • 27 Sep 2019

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals